Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of chlorpromazine on esophageal sensitivity in healthy volunteers
2016-003131-38Phase 4Completed
- Sponsor
- Targid
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in refractory gastroesophageal reflux disease (rGERD) comparing Chlorpromazine (Largactil) with Placebo (2 arms). Primary endpoint: Esophageal sensitivity assessed by multimodal stimulation. Started May 2017; status: completed.
02
Drugs
Aminazin
03
Conditions
refractory gastroesophageal reflux disease (rGERD)
Beyond the preview
Go deeper on 2016-003131-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003131-38.